- Home
- DSY vs CUE Comparison
DSY vs CUE Comparison
Compare DSY & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSY
- CUE
- Stock Information
- Founded
- DSY 2020
- CUE 2014
- Country
- DSY China
- CUE United States
- Employees
- DSY N/A
- CUE N/A
- Industry
- DSY
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- DSY
- CUE Health Care
- Exchange
- DSY Nasdaq
- CUE Nasdaq
- Market Cap
- DSY 72.0M
- CUE 59.5M
- IPO Year
- DSY N/A
- CUE 2018
- Fundamental
- Price
- DSY $1.07
- CUE $0.78
- Analyst Decision
- DSY
- CUE Strong Buy
- Analyst Count
- DSY 0
- CUE 2
- Target Price
- DSY N/A
- CUE $3.00
- AVG Volume (30 Days)
- DSY 10.3K
- CUE 120.1K
- Earning Date
- DSY 01-01-0001
- CUE 08-12-2025
- Dividend Yield
- DSY N/A
- CUE N/A
- EPS Growth
- DSY 120.37
- CUE N/A
- EPS
- DSY 0.01
- CUE N/A
- Revenue
- DSY $7,323,356.00
- CUE $8,286,000.00
- Revenue This Year
- DSY N/A
- CUE N/A
- Revenue Next Year
- DSY N/A
- CUE $10.19
- P/E Ratio
- DSY $86.83
- CUE N/A
- Revenue Growth
- DSY 16.37
- CUE N/A
- 52 Week Low
- DSY $0.95
- CUE $0.45
- 52 Week High
- DSY $6.98
- CUE $1.99
- Technical
- Relative Strength Index (RSI)
- DSY 38.83
- CUE 45.40
- Support Level
- DSY $1.03
- CUE $0.77
- Resistance Level
- DSY $1.10
- CUE $0.89
- Average True Range (ATR)
- DSY 0.06
- CUE 0.05
- MACD
- DSY 0.01
- CUE -0.00
- Stochastic Oscillator
- DSY 37.44
- CUE 15.91
About DSY Big Tree Cloud Holdings Limited Ordinary Shares
Big Tree Cloud Holdings Ltd is a consumer-oriented, mission-driven, and technology-empowered company engaged in the development, production, and sales of personal care products and other consumer goods. In particular, it is focused on the development and production of feminine pads and other feminine hygiene products. Through its platform, the company focuses on high-quality product development, deep customer engagement, and efficient sales and marketing.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.